Connor, Clark & Lunn Investment Management (CC&L)
PCVX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Vaxcyte PCVX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70,037
Closed -$8M – 1583
2024
Q3 		$8M Buy
70,037
+26,096
+59% +$2.35M 0.04% 331
2024
Q2 		$3.32M Sell
43,941
-1,825
-4% -$124K 0.01% 529
2024
Q1 		$3.13M Buy
+45,766
New +$3.17M 0.01% 546

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PCVX Position: Q4 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 70,037 shares — an estimated $8M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PCVX in Q1 2024 and held it in 3 quarters. The position peaked at $8M in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 70,037 Vaxcyte shares in Q4 2024, an estimated $8M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Vaxcyte in Q1 2024 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Vaxcyte position peaked at $8M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2024, filed 10 Feb 2025.